Jones Financial Companies Lllp Has $2.45 Million Holdings in GSK plc (NYSE:GSK)

Jones Financial Companies Lllp raised its stake in shares of GSK plc (NYSE:GSK) by 28.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 72,435 shares of the pharmaceutical company’s stock after acquiring an additional 16,185 shares during the quarter. Jones Financial Companies Lllp’s holdings in GSK were worth $2,450,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. FMR LLC raised its holdings in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC increased its stake in GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after acquiring an additional 51,378 shares during the period. Cerity Partners LLC raised its position in GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after purchasing an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC lifted its stake in GSK by 20.0% during the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after purchasing an additional 83,433 shares during the period. Institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GSK. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and lowered their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Morgan Stanley initiated coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Price Performance

Shares of GSK stock opened at $38.79 on Thursday. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The stock has a market capitalization of $80.38 billion, a PE ratio of 24.39, a PEG ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock’s fifty day moving average is $35.25 and its 200-day moving average is $37.20.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities research analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a $0.3932 dividend. This represents a $1.57 annualized dividend and a yield of 4.05%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.